Bausch Health’s Thermage technology surpasses 5 million treatments

NEW YORK - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a $2.7 billion market cap healthcare company with impressive 70% gross margins, announced Friday that its Thermage technology has reached a milestone of more than 5 million skin tightening and smoothing treatments performed worldwide.

Thermage, part of Bausch Health’s Solta Medical division, uses monopolar radiofrequency energy to heat skin layers and stimulate natural collagen production. The non-invasive technology is indicated for facial, body, and eye treatments, including the upper and lower eyelids for wrinkles. According to InvestingPro analysis, Bausch Health maintains a "GREAT" overall financial health score, with 8 additional exclusive insights available to subscribers.

"Thermage has surpassed 5 million tips used worldwide, a testament to the trusted science behind every treatment," said Jiny Kim, Senior Vice President of Solta Medical at Bausch Health, according to the company’s press release.

Thomas J. Appio, Chief Executive Officer of Bausch Health, stated that the achievement "reflects our commitment to innovative solutions in aesthetics and demonstrates the trust that patients and providers place in our products globally."

The Thermage FLX system is indicated for various dermatologic and general surgical procedures, including electrocoagulation, hemostasis, non-invasive treatment of wrinkles, temporary improvement in the appearance of cellulite, relief of minor muscle aches and spasms, and temporary improvement of local circulation.

Common side effects of Thermage treatments include mild to moderate pain during the procedure, temporary redness that typically resolves within 24 hours, and swelling that usually resolves within five days but can persist for several weeks.

Bausch Health Companies Inc. is a global pharmaceutical company that develops, manufactures, and markets products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health through its controlling interest in Bausch + Lomb. The company has demonstrated solid growth with 7.1% year-over-year revenue increase and is currently considered undervalued according to InvestingPro Fair Value metrics. Discover comprehensive analysis and detailed financial insights in the exclusive Pro Research Report, available along with 1,400+ other detailed company analyses on InvestingPro.

In other recent news, Bausch Health Companies Inc. reported its Q2 2025 earnings, revealing a robust revenue performance. The company achieved earnings per share of $0.40, significantly surpassing analyst forecasts of $0.04, marking a 900% surprise. Revenue for the quarter reached $2.53 billion, slightly exceeding expectations of $2.48 billion. In addition to its financial results, Bausch Health announced the availability of its acne treatment, CABTREO, to beneficiaries of public drug plans in Quebec and Saskatchewan. This expansion follows the treatment’s earlier availability in Ontario, Nova Scotia, and through federal government plans. These recent developments underline Bausch Health’s ongoing efforts to expand its market presence and product accessibility.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.